Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

ODYSSEY OUTCOMES Committees and Investigators, Vera A. Bittner, Michael Szarek, Philip E. Aylward, Deepak L. Bhatt, Rafael Diaz, Jay M. Edelberg, Zlatko Fras, Shaun G. Goodman, Sigrun Halvorsen, Corinne Hanotin, Robert A. Harrington, J. Wouter Jukema, Virginie Loizeau, Patrick M. Moriarty, Angèle Moryusef, Robert Pordy, Matthew T. Roe, Peter Sinnaeve, Sotirios TsimikasRobert Vogel, Harvey D. White, Doron Zahger, Andreas M. Zeiher, Ph Gabriel Steg, Gregory G. Schwartz

Research output: Contribution to journalArticlepeer-review

94 Citations (Scopus)
10 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome'. Together they form a unique fingerprint.

Medicine & Life Sciences